[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-332134-105":59,"doc-detail-332134-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","comprehensive-analysis-to-identify-pus7-as-a-prognostic-biomarker-from-pan-cancer-analysis-to-osteosarcoma-validation","Comprehensive analysis to identify PUS7 as a prognostic biomarker from pan-cancer analysis to osteosarcoma validation","","Pan-cancer research is used to characterize PUS7 (Pseudouridine Synthase 7) as a diagnostic and prognostic factor, addressing the lack of systematic evaluation across cancer types. The study integrates TCGA, GTEx, HPA, UALCAN, and TISCH to assess carcinogenic mechanisms through differential expression, survival/prognostic analyses, and biological function enrichment. Results show PUS7 overexpression across many malignancies and association with poor outcomes in multiple cancers, including osteosarcoma, where PUS7 emerges as a biomarker and potential therapeutic target.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/comprehensive-analysis-to-identify-pus7-as-a-prognostic-biomarker-from-pan-cancer-analysis-to-osteosarcoma-validation/332134/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/comprehensive-analysis-to-identify-pus7-as-a-prognostic-biomarker-from-pan-cancer-analysis-to-osteosarcoma-validation/332134.png","ImageObject",300,407,{"name":92,"@type":93},"Hazel","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main goal of the study on PUS7?","Question",{"text":112,"@type":113},"To determine whether PUS7 can serve as a diagnostic and prognostic biomarker by performing a systematic pan-cancer analysis and then validating its relevance to osteosarcoma.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which public databases are used in the analysis?",{"text":117,"@type":113},"The study uses TCGA, GTEx, Human Protein Atlas (HPA), UALCAN, and Tumor Immune Single-cell Hub (TISCH) to investigate PUS7 across cancers.",{"name":119,"@type":110,"acceptedAnswer":120},"What outcomes are linked to high PUS7 expression?",{"text":121,"@type":113},"High PUS7 expression is reported in most malignancies and correlates with poor prognosis across multiple cancer types, including osteosarcoma.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},332134,1790198205,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":36,"preview_page_count":4},137441390410,"https://ap-avatar.wpscdn.com/avatar/2000252f4ab5702993?_k=1776741390130283984","[www.aging-us.com](www.aging-us.com) AGING 2024, Vol. 16, No. 10  \nResearch Paper  \nComprehensive analysis to identify PUS7 as a prognostic biomarker from pan-cancer analysis to osteosarcoma validation  \nBaokang Dong1, Binqi Wang1, Meng Fan1, Jingyu Zhang2, Ziqin Zhao3  \n1 Department of Orthopaedics, Tianjin First Central Hospital, Nankai University, Tianjin 300192, China 2 Department of Bone Tumor and Soft Tissue Oncology, Tianjin Hospital of Tianjin University, Tianjin 300211, China 3 Department of Pathology, Tianjin Hospital of Tianjin University, Tianjin 300211, China  \nCorrespondence to: Jingyu Zhang, Ziqin Zhao; email: [Zhangjingyu2010@163.com](Zhangjingyu2010@163.com), [https://orcid.org/0000-0003-4924-6418](https://orcid.org/0000-0003-4924-6418); [starelr_99@126.com](starelr_99@126.com), [https://orcid.org/0000-0002-3942-7699](https://orcid.org/0000-0002-3942-7699)  \n[Keywords:](Keywords: pan-cancer)[ pan-cancer](Keywords: pan-cancer), PUS7, cell cycle, osteosarcoma, proliferation  \nReceived: January 4, 2024 Accepted: April 16, 2024 Published: May 30, 2024  \nCopyright: © 2024 Dong et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.  \nABSTRACT  \nAim: Pseudouridylation has demonstrated the potential to control the development of numerous malignancies. PUS7(Pseudouridine Synthase 7) is one of the pseudouridine synthases, but the literature on this enzyme is limited to several cancer types. Currently, no investigation has been performed on the systematic pan-cancer analysis concerning PUS7 role in cancer diagnosis and prognosis.  \nMethods: Employing public databases, including The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression Project (GTEx), Human Protein Atlas (HPA), UALCAN and Tumor Immune Single-cell Hub (TISCH), this work investigated the PUS7 carcinogenesis in pan-cancer. Differential expression analysis, prognostic survival analysis and biological function were systematically performed. Furthermore, PUS7 potential as anosteosarcoma biomarker for diagnosis and prognosis was assessed in this study.  \nResults: The findings indicated that PUS7 was overexpressed in the majority of malignancies. High PUS7 expression contributed to the poor prognosis among 11 cancer types, including Adrenocortical Cancer (ACC), Bladder Cancer (BLCA), Liver Cancer (LIHC), Kidney Papillary Cell Carcinoma (KIRP), Mesothelioma (MESO), Lower Grade Glioma (LGG), Kidney Chromophobe (KICH), Sarcoma (SARC), osteosarcoma (OS), Pancreatic Cancer (PAAD), and Thyroid Cancer (THCA). In addition, elevated PUS7 expression was linked to advanced TNMacross multiple malignancies, including ACC, BLCA, KIRP, LIHC and PAAD. The function enrichment analysis revealed that PUS7 participates in E2F targets, G2M checkpoint, ribosome biogenesis, and rRNA metabolic process. Moreover, PUS7 is also a reliable biomarker and a potential therapeutic target for osteosarcoma. Conclusions: In summary, PUS7 is a putative pan-cancer biomarker that reliably forecasts cancer patients’prognosis. In addition, this enzyme regulates the cell cycle, ribosome biogenesis, and rRNA metabolism. Most importantly, PUS7 possibly regulates osteosarcoma initiation and progression.  \nINTRODUCTION  \nBeing the primary cause of death worldwide, the burden of cancer morbidity and mortality is expanding dramatically [1] . In 2020, 9,958,133 casualties were reported worldwide, with 19,292,789 new cases [2] . Surgery remains the preferred treatment option, but the  \nvariety of cancer therapies has increased throughout the years. For instance, precision oncology is quickly reshaping cancer treatment guidelines as genomic analysis is widely employed for diagnostic and therapeutic purposes in multiple tumors. Furthermore, a variety of small-molecule drugs have exhibited impressive clinical efficac","cbCaiigD1uAjjUlU","https://ap.wps.com/l/cbCaiigD1uAjjUlU","pdf",4125805,16,"English","# Abstract\n## Aim\n## Methods\n## Results\n## Conclusions\n# Introduction","[{\"question\":\"What is the main goal of the study on PUS7?\",\"answer\":\"To determine whether PUS7 can serve as a diagnostic and prognostic biomarker by performing a systematic pan-cancer analysis and then validating its relevance to osteosarcoma.\"},{\"question\":\"Which public databases are used in the analysis?\",\"answer\":\"The study uses TCGA, GTEx, Human Protein Atlas (HPA), UALCAN, and Tumor Immune Single-cell Hub (TISCH) to investigate PUS7 across cancers.\"},{\"question\":\"What outcomes are linked to high PUS7 expression?\",\"answer\":\"High PUS7 expression is reported in most malignancies and correlates with poor prognosis across multiple cancer types, including osteosarcoma.\"}]","Comprehensive analysis to identify PUS7 as a prognostic biomarker from pan-cancer analysis to osteosarcoma validation | PDF",1789996947]